title: PI3King on MYCN to improve neuroblastoma therapeutics.
abstract: MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal mediated by MYCN.
authors.affiliation: Division of Oncology, Children's Hospital of Philadelphia, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA 19104, USA. hogartym@email.chop.edu
authors.forename: Michael D
authors.initials: MD
authors.lastname: Hogarty
authors.forename: John M
authors.initials: JM
authors.lastname: Maris